I n the promotion of women's reproductive health, the prevention of unintended pregnancy and of sexually transmitted infections, including HIV, is a high priority. In 2015, 87% of newly diagnosed HIV infections among women in the United States were from heterosexual transmission, 1 with poor and low-income women disproportionately represented. 2 Although unintended pregnancy has declined overall in the United States over the past 2 decades, it also has become increasingly concentrated among poor and low-income women. 3 Medicaid plays a primary role in facilitating access to reproductive health services and financing health care for poor US women. Women represent approximately 25% of HIVinfected individuals in the United States but 41% of HIV-infected Medicaid beneficiaries. 4, 5 As the only female-initiated barrier method and because gender inequities may deprive women of control over reproductive health decisions, the female condom is an essential option for women. Yet studies consistently report that its rate of use in the United States remains low, and concerns persist about the accessibility of the device. For more than 2 decades, the female condom has been a reimbursable, over-thecounter device for traditional Medicaid recipients in many states. 6 It also has been available in some states with family planning "expansion programs," addressing low-income women who are not eligible for full-benefit Medicaid. We examined state-level access to and use of the female condom through Medicaid from 2004 to 2014, including the years since passage of the ACA. We update data from an earlier survey that examined Medicaid reimbursement for the female condom through 2007.
METHODS
We replicated protocols from our earlier study examining female condom use via Medicaid by state through 2007. 6 Briefly, we collected data by telephone and e-mail, using a script, from each of the 50 state Medicaid offices individually between March 2015 and March 2016. 6 When initial contacts were unable to provide data, we asked for additional contacts from whom we might request data.
We asked the Medicaid representatives 3 questions: (1) Fourteen states, many in the Southeast, reported that they do not provide Medicaid reimbursement for the female condom.
Beginning dates of coverage varied throughout the United States; some states (e.g., Mississippi and Colorado) said that they would begin coverage "soon."
Two additional data tables (available as supplements to the online version of this article at http://www.ajph.org) provide individual and summary data from 29 (81%) of the 36 states reporting reimbursement. Table  A shows considerable variance in reporting of data and in claims per year across states. Some states provided comprehensive data across the study period; others reported data for only 1 or 2 years. Some states had thousands of claims, whereas others had few to none. Some states reimbursed hundreds of thousands of dollars, but others reimbursed less than $10 per year. In 2007, Iowa, Michigan, and Nevada showed steady increases in reimbursement, whereas more recent data show increases in some states (Iowa, Oregon, Pennsylvania) but steady decreases in others (Michigan, Minnesota, New York). Claims and reimbursement numbers do not necessarily correspond with relative state-level HIV prevalence or rates of unintended pregnancy. Table B shows cumulative claims at their highest in 2010, just before ACA passage, and declining after the 2012 contraceptive expansion.
DISCUSSION
The number of states providing Medicaid reimbursement for the female condom increased 33% (from 25 to 36) since 2007. 6 Findings suggest that the ACA expansion increased access through Medicaid. However, reported use in states providing reimbursement remains uneven, and data collection and reporting challenges persist.
The varying numbers of claims may reflect the unevenness in Medicaid expansion; in 2012, the Supreme Court determined that states could opt out of that expansion. Only in the last 5 to 10 years have many states assigned a unique Medicaid code to distinguish female from male condoms, which affects the count in data searches. A more likely reason is providers' persistent lack of awareness of the device or lack of willingness to recommend or prescribe it or a lack of awareness among consumers about their ability to request it.
2,9
One interpretive challenge is that utilization data may not accurately reflect claims and costs because some states and programs have an established or negotiated payment to managed care organizations, called capitation, which allows provision of numerous services for 1 annual fee. Therefore, decreases in claims in some states may not reflect fewer distributed female condoms.
PUBLIC HEALTH IMPLICATIONS
The ACA has theoretically increased access to the female condom for most women receiving Medicaid and all women with private insurance free of charge. Getting the device into the hands of women, however, is another matter. This period of heightened access demands that the public health community seize the moment to increase awareness about and promote the female condom among health care professionals and consumers. Apparently, female condoms are seldom claimed or reimbursed through Medicaid. We must spread awareness of the device, promote increases in provider prescriptions, and reduce persistent barriers to its use. Increasing access in states with higher HIV prevalence and unintended pregnancies may contribute to further reductions in the transmission of HIV and other sexually transmitted infections and also reduce unintended pregnancies. The pending repeal of the ACA may thwart important gains in access; policies promoting women's reproductive health must be implemented immediately.
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